Cannabinoides

Applications GW-842166X is pyrimidine ester based compound that is known as a highly selective CB2 receptor agonist for the treatment of inflammatory and neuropathic pain. References Giblin, G.M.P., et al.: J. Medn. Chem., 50, 2597 (2007)

Applications ACHMINACA is structurally similar to known synthetic cannabinoids. This product is intended for research and forensic applications.Synthetic Cannabinoids

Org 27569, an allosteric modulator of cannabinoid CB1 receptor, can induce a CB1 receptor state that is characterized by decreased inverse agonist affinity and

Cannabigerolic acid analytical standard provided with w/w absolute assay, to be used for quantitative titration.

CB1 agonist 1 is a potent CB1 agonist with a pIC50 value of 5.7 for CB1 receptors.CB1 agonist 1 can be used to study brain disorders, pain, and inflammation.

Applications CP 55,940 is a cannabinoid agonist which is considerably more potent than Δ9-THC in both behavioral tests and receptor binding assays. Displays high and roughly equal affinity for both central and peripheral cannabinoid receptors (Ki = 0.6 - 5.0 and 0.7 - 2.6 nM at CB1 and CB2 respectively; EC50 values are 0.2, 0.3 and 5 nM at CB1, CB2 and GRP55 respectively).Controlled substance. Synthetic Cannabinoids References Wiley, et al.: Neuropharmacology, 34, 669 (1995); Griffin, et al.: J. Pharmacol. Exp. Ther., 285, 553 (1998); Thomas, et al.: J. Pharmacol. Exp. Ther., 285, 285 (1998); Ryberg, et al.: Br. J. Pharmacol., 152, 1092 (2007);

Applications (4-Chloro-1-naphthalenyl)-1H-indol-3-yl-methanone is an intermediate in the synthesis of JWH-398 (J211900), a synthetic cannabimimetic indole derivative that acts as both a cannabinoid receptor CB1 and CB2 agonist. References Wiley, J.L., et al.: Biorg. Med. Chem., 20, 2067 (2012);

Carboxylic acid with phenol function

Tetrahydromagnolol can activate cannabinoid (CB) receptors.

Applications Labelled JWH 122 (P283620). An analgesic chemical which acts as a cannabinoid agonist at the CB1 and CB2 receptors. References Rituparna, S., et al.: Lett. Drug Des. Discov., 6, 599 (2009), De Freitas, G., et al.: Eur. J. Med. Chem., 44, 2482 (2009).

Applications CP-47947 (C781315) derivative. A cannabinoid receptor ligand. References Huffman, J., et al.: Bioorg Med. Chem., 9, 2863 (2001), Govaerts, S., et al.: Eur. J. Pharm. Sci., 23, 233 (2004), Bosier, B., et al.: J. Neurochem., 102, 1996 (2007),

Applications An analgesic chemical which acts as a cannabinoid agonist at the CB1 and CB2 receptors. References Tuccinardi, T., et al.: J. Med. Chem., 49, 984 (2006), Rituparna, S., et al.: Lett. Drug Des. Discov., 6, 599 (2009), De Freitas, G., et al.: Eur. J. Med. Chem., 44, 2482 (2009),

O-1269 acts as a partial agonist for the cannabinoid receptor 1 (CB1R), with a binding affinity (Ki) of 32 nM. Additionally, it exhibits analgesic properties.

Cannabigerovarinic acid is a phytocannabinoid and the precursor to tetrahydrocannabivarinic acid, cannabidivarinic acid, and cannabichromevarinic acid1. No in vitro or in vivo pharmacological and toxicological studies have been conducted on cannabigerovarinic acid.

Applications JWH 071 is a indole- derived synthetic cannabinoid (CB) agonist which binds the central CB1 receptor with higher affinity than peripheral CB2 receptor. References Wiley, J.L., et al.: J. Pharmacol. Exp. Ther. 285(3), 955 (1998);

Yangonin (Y100550) is a novel CB1 receptor ligand with affinity for human recombinant CB1 receptors.

Applications Reactant in the preparation of CB1 cannabinoid receptor agonists and brain imaging agents. References Deng, H. et al; J. Med. Chem. 48, 6386 (2005)

A selective cannabinoid receptor type 2 (CB2) agonist. Commonly, CB2 agonists induce receptor internalization, which results in desensitization and tachyphylaxis. However, APD 371 mediates efficient recycling of internalized receptors back to the plasma membrane and thus sustains analgesic effects, upon subchronic treatment, in an osteoarthritis pain model in vivo.

Cannabidivarinic acid (CBDVA), the carboxylic acid precursor to cannabidivarin (CBDV), is a non-psychoactive cannabinoid found in Cannabis and known for its anti-inflammatory properties.

Stability Very Hygroscopic Applications Paracetamol Mercapturate is a metabolite of Acetaminophen (A161220) (1,2). Acetaminophen is a widely used analgesic and antipyretic drug. It can also be used in biological study of urinary antihypertensive drug metabolite screening using molecular networking coupled to high-resolution mass spectrometry fragmentation. References (1) Trettin, A., et al.: J. Chromatogr. B., 963, 105 (2014) (2) Pickering, G., et al.: Clin. Pharmacol. Ther., 90, 707 (2011)

Amauromine is a peripherally selective and potent cannabinoid receptor type 1 (CB1) receptor antagonist, a novel alkaloid with vasodilatory activity.

Applications JWH-398 is a synthetic cannabimimetic indole derivative that acts as both a cannabinoid receptor CB1 and CB2 agonist. Synthetic Cannabinoids References Hudson, S. et al.: J. Anal. Toxicol., 34, 252 (2010); Hudson, S. et al.: Drug Test. Anal., 3, 466 (2011);

Applications 4-Hydroxypentyl AM-2201 is a metabolite of AM-2201 (A575830), is a drug which acts as a potent but unselective agonist for the cannabinoid receptor CB1 or CB2. References Yamada., et al.: J. Med. Chem., 39, 1967 (1996)

1'-Naphthoyl-2-methylindole (Compound 88) acts as a cannabinoid mimic and an inhibitor of Win 55212-2, displaying a 34% inhibition of [3H]Win 55212-2 binding to cannabinoid receptors at a concentration of 3 μM.

CB1/2 receptor-1 (compound 5.3) serves as an agonist for CB1/2 receptors and is utilized in angiogenesis research.

Bzo-poxizid is a synthetic cannabinoid and a psychoactive substance.

(±)-9-Nor-9α-hydroxy Hexahydrocannabinol is a cannabinoid-structured compound that exhibits potent cannabinoid-like activity in both dogs and mice.

Stability Hygroscopic Applications Chicoric Acid is an effective inhibitor of human immunodeficiency virus type-1 (HIV-1) integrase and the replication in tissues. Also a class of cannabinomimetics with CB2 receptor-dependent and independent References King, P. et al.: J. Virol., 72, 8420 (1998); Raduner, S. et al.: J. Biol. Chem., 281, 14192 (2006);

Halogen derivative of polyphenol

Inverse agonist of cannabinoid receptor CB1R. Taranabant was studied for its effect on smoking cessation and inducing weight loss. Serious adverse effects associated with this compound prevented further development as a drug in the clinic.

Applications JWH 122 N-(4-pentenyl) Analog is a metabolite of JWH-122 (P283620), an synthetic cannabinoid (CB) that displays high affinities for both CB1 and CB2 receptors. JWH 122 N-(4-pentenyl) Analog is also structurally related to JWH-122 N-Pentanoic Acid (J211415), JWH-122 5-Methylnaphthyl Isomer (J211410) and MAM-2201 (M265110).Synthetic Cannabinoids

Applications Labelled JWH 081 (P283600). An analgesic chemical which acts as a cannabinoid agonist at the CB1 and CB2 receptors. References Huffman, J., et al.: Bioorg. Med. Chem., 11, 539 (2003), De Freitas, G., et al.: Eur. J. Med. Chem., 44, 2482 (2009),

LY2828360: CB2 agonist, Ki=40.3 nM; biases CB2 over CB1 with EC50s of 20.1 nM and >100 μM.

Applications 1,3-Dipalmitoyl-2-chloropropanediol is used in the synthesis of some prodrugs of Piroxicam and Lornoxicam to improve their bioavailability. References Passarotti, C.M., et al.: Bollettino Chimico Farmaceutico, 134,В 161 (1995),

Virodhamine (O-arachidonoyl ethanolamine), an endocannabinoid, is an antagonist of CB1 receptor and an agonist of CB2 receptor.

Applications JWH-081 Pentanoic Acid is a metabolite of the synthetic cannabinoid JWH 081 (P283600), which is an analgesic chemical that acts as cannabinoid agonist at the CB1 and CB2 receptors. References Huffman, J., et al.: Bioorg. Med. Chem., 11, 539 (2003); De Freitas, G., et al.: Eur. J. Med. Chem., 44, 2482 (2009); Kronstrand, R., et al.: Anal. Bioanal. Chem., 406, 3599 (2014);

Voacamine: an indole alkaloid, CB1 antagonist, inhibits P-gp, may affect rhythm.

Applications (E)-5-(3,5-Bis(benzyloxy)phenyl)pent-4-en-2-ol is an intermediate used in the synthesis of 4''-Hydroxycannabidiol (H824830), which is a metabolite of Canabidiol (C175300), a major constituents in marijuana. 4''-Hydroxycannabidiol be used to investigate canabidiol metabolism and human liver microsomes that metabolize Canabidiol into 6α-Hydroxycannabidiol. References Jiang, R., et al.: Life Sci. 89, 165 (2011); Lander, N., et al.: Science 169, 611 (1970)

Stability Store in Freezer Applications 4-Pregnen-17α,20β-diol-3-one (cas# 1662-06-2) is a compound useful in organic synthesis.

Anticancer agent 110 is an anticancer compound with cytotoxic, antitumor and antileukemic activities.

CB-25 is a partial agonist ligand of CB1 cannabinoid receptors, augmenting Forskolin-induced cAMP formation in cancer cells, though not affecting hCB1-CHO cells

Applications Intermediate in the synthesis of a cannabinoid receptor ligand.

Applications Acetaminophen-13C2, 15N1 is doubly labeled Acetaminophen (A161220), an analgesic and antipyretic agent used as a pain reliever to treat headache, muscle aches, and arthritis (1,2,3). References (1) McGill, M. R. and Jaeschke, H. Pharm Res. 30, 2174 (2013)(2) Fairbrother, J.E., et al.: Anal. Profiles Drug Subs., 3, 1 (1974) (3) Hinson, J.A., et al.: Rev. Biochem. Toxicol., 2, 103 (1980)

A cannabinoid receptor agonist, which binds more selectively to CB2 than CB1 receptors (1000-fold). GW833972A inhibits vagus nerve depolarization induced by tussive agents, such as hypertonic saline (EC50 = 6.5 μM), capsaicin (EC50 = 33.9 μM) or PGE2 (EC50 = 15.9 μM).

Applications The labelled analogue of a synthetic cannabimimetic indole derivative which acts as a potent and selective agonist for the cannabinoid receptor CB1. References Willis P.G. et al.: J. Lab. Cpd. Radiopharmac., 46, 799 (2003);

Applications It is a labelled metabolite of the well-known analgesic Paracetamol. AM404 inhibits endocannabinoid cellular uptake, binds weakly to CB1 and CB2 cannabinoid receptors, and is formed by fatty acid amide hydrolase (FAAH) in vivo. References Basile, S., et al.: Pain, 52, 217 (1993), Beltramo, M., et al.: Science, 277, 1094 (1997), Bisogno, T., et al.: J. Biol. Chem., 272, 3315 (1997), Nicholson, R., et al.: Brain Res., 978, 194 (2003), La Rana, G., et al.: J. Pharmacol. Exp. Ther., 317, 1365 (2006),

GW842166X: Potent CB2 agonist, EC50=63 nM, inactive at CB1, in Phase 2 trials.